PLEASE NOTE : This is a development system.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Pyrazinamide - Tuberculosis
PAD Profile : Pyrazinamide - Tuberculosis
Keywords :
antibiotic, antibacterial, TB
Brand Names Include :
Rifater
Traffic Light Status
Status 1 of 1.
Status :
Red
Important
Formulations :
- Not Specified
Important Information :
Liaise with Chest Physician. Patients with multi-drug resistant TB should be treated by a specialist centre.
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Comments :
No comments returned.
Documents :
Guidelines
No guidelines returned.
Other Drugs
Other Indications
No indications returned.
Additional Documents
No additional documents returned.
Committee Recommendations
Date
Committee Name
Narrative
01 September 2007
Not Set
September 2007 – The DH changed the regulations and advice relating to the treatment of TB. Patients requiring TB medication should be treated in specialist TB clinics where they will not be subject to prescription charges. FP10 prescriptions are not exempt from charges and should not be used.
Associated BNF Codes
05. Infections
05.01.09. Antituberculosis drugs